Frederick Locke on Axi-cel and ZUMA-7

Frederick Locke on Axi-cel and ZUMA-7

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCLПодробнее

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

Dr. Frederick Locke at ASCO 2022: Abstract No. 7565Подробнее

Dr. Frederick Locke at ASCO 2022: Abstract No. 7565

ZUMA-7: Axi-cel en linfoma de células B grandes R/RПодробнее

ZUMA-7: Axi-cel en linfoma de células B grandes R/R

Frederick Locke: Axi-Cel Vs. Standard of Care in Aggressive LBCLПодробнее

Frederick Locke: Axi-Cel Vs. Standard of Care in Aggressive LBCL

ZUMA-7: Axi-cel in r/r large B-cell lymphomaПодробнее

ZUMA-7: Axi-cel in r/r large B-cell lymphoma

Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020Подробнее

Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020

События